Articles tagged with Ovarian Cancer
Researchers at Mount Sinai have identified a soy-based compound, genistein, that can inhibit tumor cell growth and block Wnt signaling hyperactivity in colorectal cancer. Genistein has shown promise as an adjunctive treatment for metastatic colorectal cancer when used in combination with chemotherapy.
A novel study suggests that surgical removal of an ovary and visible endometriosis significantly lower ovarian cancer risk in women with endometriosis. Hormonal treatments, however, did not show a protective effect against ovarian cancer.
Researchers developed a dual CAR approach that allows engineered T cells to selectively target tumor cells while sparing normal tissue. This innovative approach uses two separate antigen-specificity proteins, one for starting and another for boosting the immune response.
A phase I trial involving 29 patients with platinum-resistant ovarian cancer found one complete response and four partial responses to the antibody-drug conjugate DMUC5754A. The drug targets high-expression MUC16 protein in ovarian cancer cells, reducing adverse effects on healthy tissues.
A new two-step immunotherapy approach, combining dendritic cell vaccination and adoptive T-cell therapy, showed a 75% clinical benefit in 31 ovarian cancer patients. The treatment preserved tumor cells alive and used them to manufacture personalized vaccines that taught the immune system to attack the tumor.
An international study has identified up to 80 new regions of the genome associated with increased susceptibility to breast, prostate, and ovarian cancers. Researchers have also discovered a total of 41 new genes or regions that may contribute to the development of breast cancer.
Researchers have discovered five new genetic regions associated with an increased risk of ovarian cancer, found in over 40,000 women. These findings may lead to the development of new screening and prevention strategies for high-risk individuals.
Moffitt researchers have discovered four new regions of the genome linked to ovarian cancer risk, accounting for approximately 4% of inherited component. The findings are part of a coordinated series of studies involving over 250,000 individuals and provide new insights into the disease.
Researchers at Mayo Clinic Cancer Center have identified new DNA sequences linked to an increased risk of developing breast and ovarian cancers. The findings, published in three studies, will help improve risk models and support new prevention strategies for these diseases.
Researchers at Mayo Clinic Cancer Center identified the HNF1B gene as a contributor to ovarian cancer susceptibility through large-scale analysis of over 16,000 women. Variations in this gene are associated with different ovarian cancer subtypes and DNA methylation patterns.
A large-scale research study has identified over 80 genetic 'spelling mistakes' linked to an increased risk of breast, prostate, and ovarian cancers. The study found that these alterations can be described as single nucleotide polymorphisms (SNPs), which are common in the DNA of patients with cancer.
Research published in Occupational and Environmental Medicine found that night shift workers have a higher risk of developing ovarian cancer. Women who identified as 'owls' had a lower risk compared to those who were 'larks'. The study, based on data from over 1,100 women, suggests that melatonin may play a role in the increased risk.
Researchers found a population of slow-proliferating epithelial cells in the mouse ovary's hilum region that can self-renew and form tumors. These cells were previously unknown and are now believed to be the source of ovarian stem-like cells prone to cancer.
A novel stem cell niche for the ovarian surface epithelium has been identified, where ovarian carcinoma preferentially originates. This discovery provides a new guide for scientists to look for stem cell niches and sources of cancer in other transitional zones.
Women over 40 face declining fertility and require effective contraception to prevent pregnancy. Various methods are considered safe and effective, including copper IUDs, progestin implants, and sterilization, with benefits outweighing risks for most women.
Researchers found a potential therapeutic candidate, miR-506, which blocks epithelial-to-mesenchymal transition and inhibits mesenchymal markers in ovarian cancer cells. Higher miR-506 expression is associated with longer overall survival.
A phase II clinical trial shows that selumetinib, a targeted therapy, can halt growth or shrink tumors in 15% of patients with recurrent low-grade ovarian cancer. The two-year overall survival rate is 55%, and the median overall survival has not been reached due to high patient survival rates.
A two-step personalized immunotherapy treatment using dendritic cell vaccine and adoptive T cell therapy has triggered anti-tumor immune responses in patients with late-stage ovarian cancer. Four of six patients treated responded to the therapy, showing promising early results.
A preclinical study identifies Src, a master regulator of cancer cell proteins, as the key molecular switch affecting ovarian cancer progression. Beta blocker drugs mitigate this effect, reducing cancer deaths and mortality among patients with ovarian and cervical cancer.
A University of Central Florida professor has discovered a protein present in several types of cancer that could help prevent tumors from coming back. The protein, KLF8, appears to protect tumor cells from drugs and aid their regeneration.
Researchers develop SAPS algorithm to identify significant prognostic gene sets associated with patient survival, overcoming limitations of previous methods. The study found new prognostic signatures in breast and ovarian cancer subtypes, suggesting shared therapeutic targets and potential for improved diagnostics and treatments.
Researchers found that women with ovarian cancer had higher blood calcium levels than those without the disease. The study suggests that high calcium levels may be a biomarker for early detection of ovarian cancer.
Researchers at IDIBELL-Bellvitge Biomedical Research Institute have developed a new method to diagnose hereditary breast and ovarian cancer syndrome based on mass sequencing of BRCA1 and BRCA2 genes. The new protocol has been shown to be highly sensitive and specific, reducing costs and time for obtaining results.
Researchers created a genomic sequencing test, 'PapGene', using cervical fluid from routine Pap tests to detect ovarian and endometrial cancers with high accuracy. The test distinguished cancerous DNA from normal DNA, detecting both early and late-stage diseases.
Researchers at Yale School of Medicine have identified a key link between stem cell factors that fuel ovarian cancer's growth and patient prognosis. The study reveals a connection between Lin28 and BMP4, which has implications for developing novel targeted therapies.
Researchers found that Xbp1s regulates liver metabolic switch after eating, while low iron accelerates H. pylori-induced gastric cancer. Additionally, p62 is crucial for brown fat thermogenesis, and dendritic cells play a protective role in atherosclerosis.
Among eligible women, 19.1% underwent risk-reducing salpingo-oophorectomy (RRSO) and 39.6% used screening procedures, with women receiving a positive BRCA test result having increased odds of these interventions, while true-negative results were associated with reduced odds.
A nationwide survey of obstetricians and gynecologists found that many doctors perform routine pelvic exams in low-risk women due to misconceptions about ovarian cancer screening. The study suggests that the exams may be performed for non-clinical reasons, such as reassurance or expectation, rather than medical necessity.
Researchers found that ovarian cancer patients who took metformin lived significantly longer than those who did not, with a 3.7 times increased survival rate after accounting for other factors. The study suggests metformin may be considered for prevention or treatment of ovarian cancer.
A Mayo Clinic-led study found that patients with ovarian cancer who took metformin for their diabetes had a better survival rate than those who did not take the medication. After five years, 67% of metformin-takers were still alive compared to 47% of non-takers.
Researchers have found that dual-agent chemotherapy resistance in ovarian cancer arises from unique genetic changes, distinct from single-agent resistance. This discovery may lead to new strategies for overcoming resistance and improving treatment outcomes.
A study published in Cancer Discovery reveals that microRNAs can modify gene expression, converting normal fibroblasts into cancer-associated fibroblasts that promote tumor growth. The researchers identified three microRNAs involved in this process and found that inhibiting these signals could disrupt the cancer's support system.
Researchers have discovered a novel mechanism by which normal stromal cells around ovarian cancer cells are converted into cancer-promoting cells. Altering microRNA expression in these cells enhances tumor growth and metastasis, providing new potential therapeutic targets.
A UNM Cancer Center researcher is investigating the link between mitochondrial DNA and ovarian cancer. She hopes to identify genetic markers that could lead to a screening test or therapy, potentially increasing survival rates.
New research reveals that highly metastatic ovarian cancer cells are softer than less aggressive ones, suggesting cell stiffness as a valuable biomarker. This discovery could aid in the development of optimal chemotherapies for various types of cancer.
Women who regularly use aspirin have a decreased risk of serous ovarian cancer, an aggressive form of the disease. However, the benefit must be balanced against potential adverse effects of pain medication use.
Scientists at USC have discovered a new type of drug that works by targeting Protein Disulfide Isomerase (PDI) in ovarian cancer cells. The drug, PACMA31, has shown promise in reducing the number of doses needed and making it effective for patients with resistant cancer.
UNM Cancer Center researchers have identified R-ketorolac as a potential treatment for ovarian cancer cells, using flow cytometry and computer modeling to target specific GTPases. Initial animal studies show promising results in controlling tumor growth.
Researchers at Moffitt Cancer Center have discovered that microRNA miR-214 plays a critical role in regulating ovarian cancer stem cell properties. The study found that miR-214 induces the expression of a stem cell transcription factor (Nanog), leading to chemoresistance and potentially serving as a therapeutic target for ovarian cancer.
A Montreal-based research team has identified genetic patterns in ovarian cancer tumors that relate to patient survival after initial surgery. The study found that patients with mutant p53 protein had longer survival rates compared to those without.
A simple three-question paper-and-pencil survey can effectively identify women experiencing symptoms that may indicate ovarian cancer. The study involved 1,200 women and found that the screening tool identified 5% of women with a positive symptom score, resulting in one diagnosis of ovarian cancer.
The US Preventive Services Task Force recommends against annual screening for ovarian cancer in asymptomatic women due to potential harms. Reduced out-of-pocket expenses can improve medication adherence for chronic conditions, with case management and patient education showing strong evidence.
Researchers found that ovarian cancer cells hijack surrounding tissues by activating the HOXA9 gene, which induces TGF-β production and stimulates tumor growth. Blocking TGF-β expression reduced tumor growth, suggesting potential therapeutic targets for treating ovarian cancer.
MIT researchers have developed RNA-delivering nanoparticles that allow for rapid screening of new drug targets in mice. These nanoparticles target the ID4 protein, shrinking ovarian tumors in their first mouse study. The technology has the potential to relieve a significant bottleneck in cancer-drug development.
Lynn and Foster Friess are donating up to $100,000 to support ovarian cancer research at the Translational Genomics Research Institute. The challenge aims to advance cutting-edge genetic technology in pursuit of better cancer treatments.
A new study shows that ovarian grafts can maintain hormonal function for more than seven years in some women, providing a long-term solution for fertility preservation. This breakthrough could benefit young cancer survivors with premature ovarian failure, enabling them to retain reproductive health for an extended period.
A new study by UC Irvine finds significant racial and socioeconomic disparities in ovarian cancer care and survival rates. Poor women and those without insurance face significantly lower survival rates compared to their white and affluent counterparts.
A DNA repair pathway-focused score has been developed to predict chemotherapy response in ovarian cancer patients. The score is positively correlated with complete response rate, recurrence-free survival, and progression-free survival, and outperforms other clinical factors in predicting overall survival.
Scientists have identified bimodal genes acting as molecular switches in ovarian cancer, providing potential targets for clinical prognostic and diagnostic testing. These gene expressions are associated with different tumor subtypes and patient survival outcomes.
A study analyzing data from 47 studies found that increasing height increases the risk of ovarian cancer by 3% per decade. For body mass index, risks vary depending on whether women have taken menopausal hormone therapy, with an attenuated relationship in never-users.
A genetic marker in blood can determine if a patient with ovarian cancer will benefit from chemotherapy after surgery. This discovery offers hope to patients diagnosed at stage III of the disease, who have a poor prognosis without effective treatment.
A CCNY professor is evaluating MabCure Inc.'s monoclonal antibodies as a potential diagnostic reagent for ovarian cancer. The goal is to develop an early detection test that could improve the 94% five-year survival rate of the disease.
A large-scale study has identified hundreds of associations between mutations in cancer genes and sensitivity to anticancer drugs. The research may lead to more effective treatments for childhood bone cancer, such as Ewing's sarcoma, by targeting specific genetic markers.
Women with a history of endometriosis are at a significantly higher risk of developing three specific types of ovarian cancer. The study found that endometriosis is linked to a more than threefold chance of developing clear-cell ovarian cancers and over double the risk of developing endometrioid tumours.
Researchers discovered that reduced expression of OGFr accelerates tumorigenesis in human ovarian cancer. The OGF-OGFr axis plays a fundamental role in regulating cell proliferation.
A new model of aggressive ovarian cancer reveals that dendritic cells actively support tumor progression, but can be restored to suppress it. Researchers propose targeting dendritic cells to control metastatic ovarian cancer.
A study by Wayne State University School of Medicine researchers found that targeted tumor freezing therapy increases ovarian cancer survival rates, with a 56-month average survival rate reported in 98% of patients. The treatment, called cryoablation, has been shown to be cost-effective, saving an average of $26,806 per life year.
Researchers found a powerful cause-and-effect relationship between elevated platelets and ovarian cancer progression. Tumors stimulate platelet production, which strengthens the disease, reducing survival rates in patients with thrombocytosis.
The study aims to determine whether the MYC gene family is involved in the development and chemotherapy-resistance of high-grade serous ovarian cancers. Changes in MYC-family proteins have been identified as a potential cause of at least 15-20 per cent of these cancers, associated with poor clinical outcomes.
Scientists at Dana-Farber Cancer Institute have discovered a subtype of ovarian cancer that is susceptible to anti-angiogenic drugs, which block blood vessel formation. The subtype accounts for approximately one-third of all serous ovarian cancers and may benefit from therapies currently being tested in other cancers.